Evidence map›Paper›PMID 33396426›Full record

ReviewCells2020

Role of Human Mesenchymal Stem Cells in Regenerative Therapy.

Jayavardini Vasanthan, Narasimman Gurusamy, Sheeja Rajasingh, Vinoth Sigamani, Shivaani Kirankumar, Edwin L Thomas, Johnson Rajasingh

Abstract readReview
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jayavardini VasanthanDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Narasimman GurusamyDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Sheeja RajasinghDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Vinoth SigamaniDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Shivaani KirankumarDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Edwin L ThomasDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Johnson RajasinghDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0002-6172-4083

Funding

scaRNA Modified Induced Pluripotent Stem Cell-Derived Cardiomyocytes or Exosomes Therapy for Chronic Ischemic Cardiomyopathy PatientsR01HL141345 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JOHNSON, RAJASINGH · 2019 to 2022
$1.5M
NHLBI NIH HHS R01 HL141345
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) are multipotent cells which can proliferate and replace dead cells in the body. MSCs also secrete immunomodulatory molecules, creating a regenerative microenvironment that has an excellent potential for tissue regeneration. MSCs can be easily isolated and grown in vitro for various applications. For the past two decades, MSCs have been used in research, and many assays and tests have been developed proving that MSCs are an excellent cell source for therapy. This review focusses on quality control parameters required for applications of MSCs including colony formation, surface markers, differentiation potentials, and telomere length. Further, the specific mechanisms of action of MSCs under various conditions such as trans-differentiation, cell fusion, mitochondrial transfer, and secretion of extracellular vesicles are discussed. This review aims to underline the applications and benefits of MSCs in regenerative medicine and tissue engineering.

Indexed as

Cell DifferentiationExtracellular VesiclesHumansInduced Pluripotent Stem CellsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationRegenerative MedicineTissue Engineeringdifferentiationmesenchymal stem cellsregenerative therapytissue engineering

Identifiers

PMID33396426
PMCPMC7823630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.